LLY241213C930000
- 0.01
- 0.000.00%
Eli Lilly and Co Newsroom
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says
EMA: Eli Lilly and Co (LLY.US) weight loss drug Mounjaro can also treat sleep apnea without the need for additional indications.
An expert group from the European Union's pharmaceutical regulatory agency EMA has determined that Eli Lilly and Co's weight loss drug Mounjaro does not require a separate indication for the treatment of obstructive sleep apnea (OSA).
US Stock Outlook | Is the unemployment rate in the USA showing warning signs? Societe Generale warns: there will be a risk of recession next year; AI chip stocks are soaring in pre-market, Broadcom has risen over 17% after earnings.
Meta has released a new AI model that will enhance the Metaverse experience; with multiple Bullish factors combined, Taiwan Semiconductor rose over 2% in pre-market trading; Eli Lilly and Co's Mounjaro has replaced Novo-Nordisk A/S's Wegovy, becoming the new favorite weight loss drug in the United Kingdom.
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Express News | Eli Lilly and Co - European Commission Decision on Omvoh Expected in Next 1-2 Months
Express News | Eli Lilly and Co - Expects U.S. Decision on Omvoh for Crohn's Disease in H1 2025
Express News | Lilly's Omvoh® (Mirikizumab) Recommended by Chmp for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease
Express News | EMA's Chmp: Finalised Assessment of Application to Extend Use of Mounjaro to Include Treatment of Obstructive Sleep Apnoea in Adults With Obesity
Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.
The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.
Lilly's Omvoh (Mirikizumab) Recommended by CHMP for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease
Trump rings the opening bell for the NYSE: The stock market is everything, and significant actions will be taken regarding Cryptos.
On Thursday, Donald Trump rang the opening bell at the NYSE. He emphasized the importance of the stock market, stating that the stock market is everything, and plans to take significant actions regarding Cryptos, lower the corporate tax rate to 15%, and increase Petroleum Extraction to alleviate the current inflationary pressures.
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
"Person of the Year" Trump rings the opening bell at the NYSE, emphasizing that "the stock market is everything."
On December 12, the elected President Trump was named Time Magazine's Person of the Year for 2024, ringing the opening bell at the NYSE that day; Trump rang the bell with the CEO of ICE and the CEO of Time Magazine, along with the president of the NYSE, while the CEOs of companies such as Goldman Sachs and Citigroup were present; Trump promised an "unprecedented economy," planned to increase oil drilling to reduce inflation, and committed to lowering the corporate tax rate to 15%.
Top 20 by transaction volume | Performance guidance fell short of expectations, Adobe dropped nearly 14%; MicroStrategy fell over 4%.
On Thursday, the top stock by trading volume in the U.S. market was Tesla, which closed down 1.57% with a trading volume of 36.778 billion USD; the second was NVIDIA, which closed down 1.41% with a trading volume of 21.623 billion USD; the eleventh was UnitedHealth Group, which closed down 3.33% with a trading volume of 4.899 billion USD.
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound